C4 Therapeutics reports Q1 EPS (65c), consensus (58c)

Reports Q1 revenue $7.7M, consensus $8.05M. "The recent commencement of patient dosing in the Phase 1 ADVANCED-1 trial of TARA-002 for non-muscle invasive bladder cancer marked an important step toward our goal of bringing a much needed, novel therapeutic option to this underserved population," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "Beyond NMIBC, we are encouraged to have recently held a meeting with the U.S. Food and Drug Administration, where we received preliminary guidance regarding a development path for TARA-002 in lymphatic malformations. We are currently planning to initiate a Phase 2 clinical trial in this indication subject to alignment with FDA on a clinical trial protocol. We also remain very engaged with the LMs treating community as we work to design a clinical study that will further progress our program for this rare pediatric indication that currently lacks any FDA-approved therapies."